NSPR INSPIREMD INC

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.

Presentation details:

Date:Wednesday, April 10th
  
Time:8:00-8:40 AM ET
  
Webcast:, or on the Events section of the company’s Investor Relations website at .
  

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390





EN
03/04/2024

Underlying

NSPRINSPIREMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INSPIREMD INC

 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Report First Quarter 2024 Financial Results and Provide C...

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open.   Management will host a conference call and webcast with the i...

May 7, 2024 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Con...

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024. Presentation details: Date:Wednesday, April 10th  Time:8:00-8:40 AM ET  Webcast:, or on the Events section of the company’s Inv...

April 3, 2024 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-...

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Le...

March 26, 2024 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results ...

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TC...

March 6, 2024 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Result...

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th -Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open. ...

February 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch